Pharmacyclics/Janssen win FDA nod for Imbruvica in CLL
This article was originally published in Scrip
Executive Summary
Pharmacyclics and Janssen Biotech, part of Johnson & Johnson, won the FDA's approval on 12 February to market Imbruvica (ibrutinib) as a treatment for patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy.